by Cal Strode | Aug 16, 2023
In a wide-ranging interview with POLITICO reporter Robert King at the Next Generation of Health Care Therapies event, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), discussed cell and gene...
by Cal Strode | Jul 12, 2023
In 2017, Signals’ blog carnival focused on Right to Try (RTT) legislation – laws that allow patients with life-threatening conditions to ask drugmakers for medicines that have cleared some testing hurdles, but still haven’t been approved by the U.S. Food and Drug...
by Stacey Johnson | Jun 16, 2023
The definition of a rare disease in the U.S. is under 200,000 patients. The 10 per cent of Americans living with a rare disease is equivalent to 30 million people. Put another way, that is close to the entire population of Canada (at 39 million). There are 7,000 –...
by Cal Strode | May 18, 2023
Regular readers of Alliance for Regenerative Medicine (ARM) sector reports may have noticed that the organization is taking a new approach to sharing insights on the cell and gene therapy sector. In April, ARM launched a new format for distilling key data and trend...
by Stacey Johnson | Jan 27, 2023
Last year saw the organizers behind Advanced Therapies Week (ATW) move the conference from Miami to Miami Beach to accommodate a larger audience. As the Covid-19 pandemic was still going strong in January 2022, making international travel more difficult, attendance...
Comments